Akira Komoriya

This inventor holds 16 USPTO granted patents and 7 published patent applications and 1 EPO patent. Top assignees: Oncoimmunin Inc., Johns Hopkins University, Oncolmmunin Inc.. Active years: 1988-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Akira Komoriya. Retrieved from https://idiyas.com/inventor/akira-komoriya

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 7)

% Patents Active = 87.5

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 2.1

ph-index = 9

Forward Citations = 251(Granted Patents)

Location History:

Rockville, MD (US) (1988 - 2011)
Potomac, MD (US) (2007 - 2022)

Company Filing History:

Johns Hopkins University

The United States of America as Represented by the Department of Health

patents

5. 1 out of 2,202

The United States of America as Represented by the Secretary of

patents

Years Active: 1988-2022

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11261443 - In vivo delivery of oligonucleotides (2022-03-01),

2. 10557136 - In vivo delivery of oligonucleotides (2020-02-11),

3. 7927871 - Visualization and quantitation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers (2011-04-19),

4. 7879574 - Compositions for the detection of enzyme activity in biological samples and methods of use thereof (2011-02-01),

5. 7541143 - Homo-doubly labeled compositions for the detection of enzyme activity in biological samples (2009-06-02),

6. 7312302 - Compositions for the detection of enzyme activity in biological samples and methods of use thereof (2007-12-25),

7. 6936687 - Compositions for the detection of enzyme activity in biological samples and methods of use thereof (2005-08-30),

8. 6893868 - Homo-doubly labeled compositions for the detection of enzyme activity in biological samples (2005-05-17),

9. 6037137 - Fluorogenic peptides for the detection of protease activity (2000-03-14),

10. 5714342 - Compositions for the detection of protease in biological samples and (1998-02-03),

11. 5635356 - Anti-oncoimmunin-M antibodies and uses thereof (1997-06-03),

12. 5605809 - Compositions for the detection of proteases in biological samples and (1997-02-25),

13. 5364619 - Oncoimmunins (1994-11-15),

14. 5055561 - Protein label and drug delivery system (1991-10-08),

15. 4889916 - Protein label and drug delivery system (1989-12-26),

Title: Exploring the Innovations of Inventor Akira Komoriya

Introduction

Akira Komoriya is a distinguished inventor based in Potomac, MD, recognized for his contributions to the field of biotechnology. With an impressive portfolio of 16 patents, he has made significant strides in developing innovative methods for the delivery of nucleic acid sequences, contributing to advancements in genetic research and therapies.

Latest Patents

One of Akira Komoriya's latest patents focuses on the in vivo delivery of oligonucleotides. This groundbreaking invention introduces a method that utilizes one or more hydroxyethyl starch (HES) molecules linked to an oligonucleotide, enabling the effective delivery of a nucleic acid sequence into the cytoplasm of cells and tissues of living organisms. The delivery vehicle is designed to be nontoxic to cells, ensuring safety during application. The technology is noteworthy for its sequence-independent delivery mechanism that crosses cellular membranes without the need for receptors. This allows for targeting complementary sequences both in the cytoplasm and the nucleus of live cells. The method holds promise for various applications, including the delivery of genes for protein expression, antisense oligonucleotides, siRNAs, shRNAs, Dicer substrates, miRNAs, anti-miRNAs, or any nucleic acid sequence in living organisms, including mammals, plants, and even microorganisms such as bacteria and viruses.

Career Highlights

Throughout his career, Akira Komoriya has worked with reputable companies such as Oncoimmunin Inc. and The Johns Hopkins University. His expertise in biotechnological advancements has made him a pivotal figure in his field, influencing research and applications that pave the way for innovative solutions in medicine and genetics.

Collaborations

In his professional journey, Komoriya has collaborated with notable coworkers, including Beverly S Packard and Michael Edidin. These collaborations have allowed for the exchange of ideas and knowledge, further enriching the impact of his work and contributions to the scientific community.

Conclusion

Akira Komoriya's inventive spirit and commitment to enhancing our understanding and application of biotechnology are evident through his extensive patent portfolio. His latest innovations in the delivery of oligonucleotides represent a significant leap forward in genetic research, with potential applications across various fields. As he continues to push the boundaries of what is possible, Komoriya remains a key figure to watch in the realm of biotech innovations.

Profile summary based on public USPTO records.